Suedia - suedeză - Läkemedelsverket (Medical Products Agency)

medartuum ab - dexametasonnatriumfosfat - Ögondroppar, lösning i endosbehållare - 1 mg/ml - dexametasonnatriumfosfat 1,093 mg aktiv substans

Suedia - suedeză - Läkemedelsverket (Medical Products Agency)

2care4 aps - dexametasonnatriumfosfat - Ögondroppar, lösning i endosbehållare - 1 mg/ml - dexametasonnatriumfosfat 1,093 mg aktiv substans

Suedia - suedeză - Läkemedelsverket (Medical Products Agency)

abboxia ab - dexametasonnatriumfosfat - injektions-/infusionsvätska, lösning - 4 mg/ml - dexametasonnatriumfosfat 4,37 mg aktiv substans; hydroxipropylbetadex hjälpämne

Suedia - suedeză - Läkemedelsverket (Medical Products Agency)

2care4 aps - dexametason - tablett - 4 mg - dexametason 4 mg aktiv substans; laktosmonohydrat hjälpämne

Suedia - suedeză - Läkemedelsverket (Medical Products Agency)

ebb medical ab - dexametason - tablett - 4 mg - dexametason 4 mg aktiv substans; laktosmonohydrat hjälpämne

Uniunea Europeană - suedeză - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; lymphoma, follicular - immunsuppressiva - multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) är indicerat för behandling av vuxna patienter med tidigare obehandlat multipelt myelom som inte är berättigade till transplantation. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) är indicerat för behandling av vuxna patienter med tidigare obehandlat multipelt myelom som inte är berättigade till transplantation. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Uniunea Europeană - suedeză - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; myelodysplastic syndromes; lymphoma, follicular; lymphoma, mantle-cell - immunsuppressiva - multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) är indicerat för behandling av vuxna patienter med tidigare obehandlat multipelt myelom som inte är berättigade till transplantation. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 och 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) är indicerat för behandling av vuxna patienter med tidigare obehandlat multipelt myelom som inte är berättigade till transplantation. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 och 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Suedia - suedeză - Läkemedelsverket (Medical Products Agency)

orion corporation - kaspofunginacetat - pulver till koncentrat till infusionsvätska, lösning - 70 mg - kaspofunginacetat 77,69 mg aktiv substans; sackaros hjälpämne; mannitol hjälpämne

Suedia - suedeză - Läkemedelsverket (Medical Products Agency)

orion corporation - kaspofunginacetat - pulver till koncentrat till infusionsvätska, lösning - 50 mg - kaspofunginacetat 55,52 mg aktiv substans; sackaros hjälpämne; mannitol hjälpämne

Suedia - suedeză - Läkemedelsverket (Medical Products Agency)

laboratorios lorien s.l. - kaspofunginacetat - pulver till koncentrat till infusionsvätska, lösning - 70 mg - mannitol hjälpämne; sackaros hjälpämne; kaspofunginacetat 77,69 mg aktiv substans